Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aligos Therapeutics Inc ALGS

Healthcare Biotechnology
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases. The Company discovers and develops therapeutics for metabolic dysfunction associated steatohepatitis (MASH) and viruses with high unmet medical need, such as chronic hepatitis B (CHB) and coronaviruses. Its advanced drug... see more

Recent & Breaking News (NDAQ:ALGS)

Aligos Therapeutics Begins Dosing with NASH Drug Candidate, ALG-055009, in Healthy Volunteers in a Phase 1 First-in-Human Study

GlobeNewswire December 9, 2021

Aligos Presents Update of Chronic Hepatitis B Pipeline Portfolio at HEP DART 2021

GlobeNewswire December 7, 2021

Vipergen Establishes Research Partnership with Aligos Therapeutics Focused on DNA Encoded Library (DEL)-Based Drug Discovery for Viral Infections and Liver Diseases

PR Newswire November 23, 2021

Aligos Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

GlobeNewswire November 22, 2021

Aligos Therapeutics Appoints Bridget Martell, MA, M.D., to its Board of Directors

GlobeNewswire November 18, 2021

Aligos Therapeutics to Present Virtually at the Jefferies London Healthcare Conference 2021

GlobeNewswire November 15, 2021

Aligos Therapeutics Presents Data for its Chronic Hepatitis B (CHB) and Nonalcoholic Steatohepatitis (NASH) Portfolio at The Liver Meeting® 2021

GlobeNewswire November 12, 2021

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2021 Financial Results

GlobeNewswire November 4, 2021

Aligos Therapeutics to Announce Third Quarter 2021 Results November 4, 2021

GlobeNewswire October 28, 2021

Aligos Therapeutics to Present Data for its Clinical Portfolio Targeting Chronic Hepatitis B and NASH at AASLD'S The Liver Meeting® 2021

GlobeNewswire October 14, 2021

Aligos Therapeutics Begins Dosing with Antisense Oligonucleotide Drug Candidate, ALG-020572, in Healthy Volunteers in a Phase 1 Proof-of-Concept Study

GlobeNewswire October 11, 2021

Aligos Therapeutics to Present at the Cantor Virtual Global Healthcare Conference

GlobeNewswire September 20, 2021

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2021 Financial Results

GlobeNewswire August 5, 2021

Aligos Therapeutics to Announce Second Quarter 2021 Results August 5, 2021

GlobeNewswire July 29, 2021

Aligos Therapeutics Announces Pricing of $83.6 Million Public Offering of Common Stock

GlobeNewswire June 30, 2021

Aligos Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire June 28, 2021

Aligos Therapeutics to Present Phase 1 Safety and Pharmacokinetic Data for STOPS(TM) Molecule Drug Candidate ALG-010133 and Several Nonclinical Chronic Hepatitis B Programs at the European Association for the Study of the Liver's Digital International Liver Congress 2021

GlobeNewswire June 21, 2021

Aligos Therapeutics Announces Pipeline Update and Upcoming Presentations at the European Association for the Study of the Liver's Digital International Liver Congress 2021

GlobeNewswire June 14, 2021

Aligos Therapeutics to Present Preliminary Antiviral Activity of ALG-000184 in Chronic Hepatitis B (CHB) Subjects at HBV-TAG Conference

GlobeNewswire June 10, 2021

Aligos Therapeutics to Present at the Jefferies Virtual Healthcare Conference

GlobeNewswire May 20, 2021